Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Net Income Loss of -$18.47 million for the year ending 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -495.0% in Net Income Loss from 2021 to 2022.
- This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
- XBRL data for this metric is available from 2010 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2010 to 2022), ENDONOVO THERAPEUTICS, INC.'s Net Income Loss has declined by 26,520.8%.
- Historical annual values: Fiscal year 2022: -$18.47 million | Fiscal year 2021: -$3.10 million | Fiscal year 2020: -$395.6 thousand | Fiscal year 2019: -$17.31 million | Fiscal year 2018: -$6.44 million | Fiscal year 2017: -$10.81 million | Fiscal year 2016: -$5.32 million | Fiscal year 2015: -$6.77 million | Fiscal year 2014: -$959.5 thousand | Fiscal year 2011: -$94.1 thousand | Fiscal year 2010: -$69.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: